It aims to develop less invasive and more accurate screening tools, so cancer can be treated at its earliest stage. Read more ...

Well, that's exactly what Grail ( GRAL 0.41%) makes. Its multicancer early detection (MCED) test -- called Galleri -- screens ...

Guardant’s screen could see annual sales of $50 billion. The company hopes to use the technology to detect hundreds of other diseases.

The included studies provided insufficient evidence on the prediagnostic and diagnostic accuracy of multicancer detection ...

Gaize showcases safety professionals an alternative to traditional drug testing at NSC, with real-time detection of ...

Equipped with both standard and emerging technologies such as gas chromatography–mass spectrometry (GC–MS), Fourier transform ...